Graphite Bio Announces Participation in Upcoming Investor Conferences

Author's Avatar
Jan 27, 2022

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced participation in the following upcoming investor conferences: